2023
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal Of Cancer 2023, 185: 178-215. PMID: 37003085, DOI: 10.1016/j.ejca.2023.02.018.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate Cancer Consensus ConferenceAdvanced prostate cancerHormone-sensitive prostate cancerOligometastatic prostate cancerProstate cancerNon-metastaticConsensus conferenceConsensus questionsTreatment optionsMetastatic hormone-sensitive prostate cancerAdvanced prostate cancer managementInternational prostate cancer expertsLocally advanced prostate cancerAdvanced prostate cancer treatmentEffects of hormone therapySide effects of hormone therapyMetastatic hormone-sensitiveOligoprogressive prostate cancerProstate cancer expertsProstate cancer managementLevel 1 evidenceNovel treatment options
2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, N. K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O’Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology 2022, 83: 267-293. PMID: 36494221, PMCID: PMC7614721, DOI: 10.1016/j.eururo.2022.11.002.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceAdvanced prostate cancerProstate Cancer Consensus ConferenceLocally advanced prostate cancerCastration-resistant prostate cancerProstate cancerBiochemical relapseSide effectsHormone therapyTreatment optionsMetastatic hormone-sensitive prostate cancerNonmetastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerClinical managementInternational prostate cancer expertsLack high-level evidenceHormone-sensitive prostate cancerProstate cancer treatment decision-makingTreatment decisionsHigh riskConsensus conferenceOligoprogressive prostate cancerProstate cancer expertsLocally advanced diseaseManagement of patientsManagement of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology 2022, 82: 115-141. PMID: 35450732, DOI: 10.1016/j.eururo.2022.04.002.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceProstate Cancer Consensus ConferenceAdvanced prostate cancerMetastatic hormone-sensitive prostate cancerProstate cancerConsensus conferenceTreatment optionsDiagnosed metastatic hormone-sensitive prostate cancerManagement of advanced prostate cancerTreatment of advanced prostate cancerProstate-specific membrane antigen ligandHormone-sensitive prostate cancerInternational prostate cancer expertsConsensus questionsProstate cancer expertsLevel 1 evidenceManagement of patientsLocation of diseaseExpert panel votesClinically relevant areasSupplementation guidelinesClinical evidencePatient characteristicsAntigenic ligandsClinical trials
2020
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Gillessen S, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Chi K, Clarke N, Davis I, de Bono J, Drake C, Duran I, Eeles R, Efstathiou E, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano C, Hofman M, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli R, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Reiter R, Roach M, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Small E, Smith M, Soule H, Sternberg C, Steuber T, Suzuki H, Sweeney C, Sydes M, Taplin M, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology 2020, 77: 508-547. PMID: 32001144, DOI: 10.1016/j.eururo.2020.01.012.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceAdvanced prostate cancerProstate Cancer Consensus ConferenceCastration-resistant prostate cancerProstate cancer expertsProstate cancerConsensus questionsManagement of advanced prostate cancerMetastatic castration-resistant prostate cancerNonmetastatic castration-resistant prostate cancerInternational prostate cancer expertsAdvanced prostate cancer treatmentCancer expertsEffects of hormone therapyConsensus conferenceAdverse effects of hormone therapyLocally advanced diseaseProstate cancer managementLevel 1 evidenceProstate cancer treatmentManagement of patientsPatient-specific factorsClinical trial enrollmentMultidisciplinary decision makingBiochemical recurrence
2017
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Gillessen S, Attard G, Beer T, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung B, Clarke N, Daugaard G, Davis I, de Bono J, dos Reis R, Drake C, Eeles R, Efstathiou E, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano C, James N, Kantoff P, Kellokumpu-Lehtinen P, Khauli R, Kramer G, Logothetis C, Maluf F, Morgans A, Morris M, Mottet N, Murthy V, Oh W, Ost P, Padhani A, Parker C, Pritchard C, Roach M, Rubin M, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg C, Suzuki H, Sweeney C, Sydes M, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology 2017, 73: 178-211. PMID: 28655541, DOI: 10.1016/j.eururo.2017.06.002.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceAdvanced prostate cancerProstate cancerAdvanced prostate cancer managementInternational prostate cancer expertsProstate Cancer Consensus ConferenceLocally advanced prostate cancerCastration-resistant prostate cancerProstate cancer expertsConsensus questionsOsteoclast-targeted therapyLow level of evidenceManagement of patientsMultidisciplinary decision-making processManagement of menPrimary clinical relevanceIndividualised treatment decisionsLevel of evidenceTreatment of menProstate cancer drugsDisease extentTreatment optionsClinical trialsSide effectsCancer experts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply